Colchicine myopathy and neuromyopathy: two cases with different characteristics

J Clin Rheumatol. 2010 Aug;16(5):229-32. doi: 10.1097/RHU.0b013e3181e96342.

Abstract

Colchicine, a long established anti-inflammatory agent now used in several rheumatologic conditions, acts by inhibiting microtubular polymerization, as it binds equimolarly to tubulin molecules. Cytoskeletal microtubules are crucial in processes of cell viability, such as mitosis and intracellular vesicle motility.Gastrointestinal side effects are quite common and often minor in nature or duration, whereas neuromuscular toxicity is rare. We report 2 cases of colchicine myopathy in the context of very different clinical settings.

Publication types

  • Case Reports

MeSH terms

  • ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism
  • Adolescent
  • Arthritis, Gouty / drug therapy
  • Colchicine / adverse effects*
  • Colchicine / metabolism
  • Colchicine / therapeutic use
  • Cytochrome P-450 CYP3A / metabolism
  • Familial Mediterranean Fever / drug therapy
  • Female
  • Humans
  • Male
  • Middle Aged
  • Muscle Weakness / chemically induced
  • Muscle Weakness / diagnosis
  • Muscular Diseases / chemically induced*
  • Muscular Diseases / diagnosis
  • Tubulin Modulators / adverse effects*
  • Tubulin Modulators / metabolism
  • Tubulin Modulators / therapeutic use

Substances

  • ATP Binding Cassette Transporter, Subfamily B, Member 1
  • Tubulin Modulators
  • Cytochrome P-450 CYP3A
  • CYP3A4 protein, human
  • Colchicine